When Should a Therapist Refer a Client for Neuromodulation Therapy?

Direct Answer

The usual threshold is two or more adequate medication trials without remission, but four other situations justify a referral conversation earlier. Side effects that are limiting adherence or quality of life. Partial response where symptoms improve but function does not recover. A client who declines medication or cannot tolerate it. And a course that has plateaued in psychotherapy despite consistent engagement. In each case the referral is a question rather than a decision, since candidacy is determined by the treating psychiatrist or the neuromodulation service, not by the referring therapist.

Two points matter before making the call. First, confirm that prior trials were genuinely adequate in dose and duration, because a substantial share of apparent treatment resistance is under-treatment rather than non-response. Second, neuromodulation in outpatient practice is generally adjunctive. It is delivered alongside continuing psychotherapy and medication rather than instead of them, and in most cases the referring therapist keeps the therapeutic relationship.

The Case for Referring Earlier Than Feels Natural

The instinct is to keep adjusting before escalating, and the sequential trial data argue against waiting too long. In the STAR*D study of outpatients with major depression, remission rates fell with each successive treatment step: 36.8 percent at step one, 30.6 percent at step two, 13.7 percent at step three and 13.0 percent at step four.¹ After two failed steps, the probability that the third or fourth medication change produces remission is roughly one in seven.

The longer-term finding is the more important one. Relapse rates were higher for patients who entered follow-up after more treatment steps, and their time to relapse was shorter, regardless of whether they had achieved remission.¹ Needing more steps did not simply delay recovery. It predicted a more fragile recovery. That is an argument for widening the treatment approach after two adequate trials rather than continuing to iterate within the same one.

What Counts as an Adequate Trial

This is where most referral conversations should start, and where many go wrong. An adequate trial means a therapeutic dose sustained for a sufficient duration with documented adherence. A client who took a low starting dose for three weeks, stopped because of nausea and never returned has not had a failed trial. They have had an interrupted one, and the appropriate next step may be a different medication or better side-effect management rather than a neuromodulation referral.

Apparent non-response also has confounds worth ruling out before escalating. Untreated substance use is the most common of them in this age group, and SAMHSA’s treatment improvement protocol on co-occurring disorders recommends screening for substance use disorders, mental disorders, risk of harm to self and others, functional impairment and trauma rather than assuming any one of them has been addressed.⁵ A client whose depression has not responded to two trials while drinking heavily has a different problem than one who is treatment resistant.

As the referring clinician you are often the only person with the longitudinal view of what was actually taken and for how long. Reconstructing that history before the referral, including doses, durations and the reason each medication ended, changes the quality of the consultation more than any other single thing you can contribute.

What the Referral Actually Involves

Clients ask, and a therapist who can answer accurately reduces the drop-off between referral and first appointment. Repetitive transcranial magnetic stimulation is FDA-cleared for treatment-resistant depression, obsessive compulsive disorder, anxious depression and smoking dependence.² A typical session runs from a few minutes to around 40 minutes, and a standard course involves daily sessions five days a week for four to six weeks, with accelerated protocols compressing that further.²

Side effects are generally local and mild, most commonly discomfort at the treatment site, contraction or tingling of scalp, jaw or facial muscles, brief headache and lightheadedness.² The practical burden for a client is the schedule rather than the procedure. Twenty to thirty weekday appointments is a real commitment for someone in school or working, and raising it early prevents a referral from stalling at the logistics stage.

Age Matters and the Clearances Are Specific

For clients in their late teens and early twenties, the regulatory picture changed recently. In March 2024 the FDA cleared the NeuroStar Advanced Therapy System as an adjunct for the treatment of major depressive disorder in adolescent patients aged 15 to 21.³ That clearance is device-specific and indication-specific, and it is an adjunct clearance rather than a standalone one.

The general lesson for referrers is to ask which device and which cleared indication apply to the client in front of you, rather than treating TMS as a single undifferentiated intervention. Deep TMS systems carry their own clearances that differ from standard rTMS systems, and a service treating a 17-year-old is working under different clearance conditions than one treating a 30-year-old. Yellowbrick provides neuroscience and neuromodulation services through an agreement with its sister company Synchrony Brain Health, whose outpatient services include deep transcranial magnetic stimulation, neurofeedback, cognitive enhancement and genetic analysis for medication consultation. Questions about device, cleared indication and age criteria should be directed to that service before a client is told what to expect.

Where Pharmacogenetic Testing Fits

Pharmacogenetic testing is frequently offered alongside neuromodulation services and is worth understanding as a separate question. It analyses genetic variants affecting drug metabolism and can inform medication selection, dosing and interaction risk. It is a tool for refining pharmacotherapy rather than a form of neuromodulation, and it is most useful where the history includes unusual side-effect sensitivity, unexpectedly poor response at standard doses or repeated intolerance across agents.

Set expectations carefully with clients. Testing describes metabolic tendencies. It does not identify which medication will work, and results are one input into prescribing rather than a decision rule. Where a client arrives asking for testing because they have read that it will end the trial-and-error process, correcting that framing before the referral prevents disappointment afterward.

Referral Triggers and Where to Look Next

What to Prepare Before You Make the Referral

• Reconstruct the medication history with doses, durations and the specific reason each agent ended.
• Distinguish trials that failed from trials that were interrupted, and say which is which in the referral.
• Document current symptoms and, separately, current functioning, since candidacy discussions often turn on the second.
• Note any prior neuromodulation, including partial courses and why they ended.
• Screen for the practical constraints first: can this client attend appointments five days a week for several weeks?
• Ask the client what they have already read or been told about the modality, and correct it before the consultation.
• Confirm who is prescribing now and whether that prescriber is aware of the referral.
• Clarify with the client that you intend to continue as their therapist, if that is your intention.
• Ask the service which device and cleared indication apply, particularly for a client under 22.
• Request that the consultation report come back to you, and obtain the release that makes that possible.

Key Takeaway

Refer when two adequate trials have not produced remission, and consider referring earlier when side effects are limiting, when function has not recovered despite symptom response, when a client declines medication or when therapy has plateaued. The sequential trial evidence supports not waiting: remission rates fall steeply after the second step and patients who need more steps relapse sooner. Before referring, verify that prior trials were adequate in dose and duration, because under-treatment is commonly mistaken for treatment resistance. Frame the referral as adjunctive, since neuromodulation is delivered alongside continuing therapy and medication in most cases. Where a client needs more than an outpatient procedure, programs providing assessment and graduated levels of care for this age range, such as Yellowbrick’s emerging adult services, are the more appropriate first call.

Clinical Note

This article is general guidance for referring clinicians. It is not a substitute for individual clinical judgment or an individualized assessment, it does not establish candidacy for any procedure and it does not constitute medical advice. Candidacy, device selection and treatment decisions rest with the treating physician and the neuromodulation service. FDA clearances are device-specific and indication-specific and change over time, so confirm current clearance, protocol and age criteria directly with the service.

If a client is in immediate danger, direct them to emergency services. The 988 Suicide and Crisis Lifeline provides free, confidential crisis support 24 hours a day, seven days a week, by call or text to 988.⁴

Glossary

• Neuromodulation: an umbrella term for interventions that alter neural activity directly, including transcranial magnetic stimulation, neurofeedback and other brain stimulation therapies.
• Repetitive transcranial magnetic stimulation (rTMS): delivery of repeated magnetic pulses to targeted cortical regions across a course of sessions.
• Deep transcranial magnetic stimulation (dTMS): a variant using coil designs intended to reach deeper cortical targets, with device-specific FDA clearances.
• Adequate trial: a therapeutic dose of a medication sustained for a sufficient duration with documented adherence.
• Treatment-resistant depression: depression that has not remitted after an accepted number of adequate trials, most commonly defined as two.
• Adjunct clearance: an FDA clearance for use alongside another treatment rather than as a standalone therapy.
• Pharmacogenetic testing: analysis of genetic variants affecting drug metabolism, used to inform medication selection and dosing rather than to predict response.

References

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. “Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report.” American Journal of Psychiatry, vol. 163, no. 11, November 2006. Accessed August 25, 2026. https://psychiatryonline.org/doi/10.1176/ajp.2006.163.11.1905.
2. National Institute of Mental Health. “Brain Stimulation Therapies.” NIMH Health Topics, last reviewed March 2024. Accessed August 25, 2026. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.
3. U.S. Food and Drug Administration. “NeuroStar Advanced Therapy System, 510(k) Premarket Notification K231926.” Neuronetics, Inc., cleared March 22, 2024. Accessed August 25, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf23/K231926.pdf.
4. 988 Suicide and Crisis Lifeline. Operated in partnership with the Substance Abuse and Mental Health Services Administration and Vibrant Emotional Health. Accessed August 25, 2026. https://988lifeline.org/.
5. Substance Abuse and Mental Health Services Administration. “TIP 42: Substance Use Treatment for Persons With Co-Occurring Disorders.” Publication No. PEP20-02-01-004, March 2020. Accessed August 25, 2026. https://library.samhsa.gov/product/tip-42-substance-use-treatment-persons-co-occurring-disorders/pep20-02-01-004.

Learn more about Yellowbrick Consultation and Treatment Center on Google.